Takeda Pharmaceutical Co Ltd
TAK15.145USD
+0.085+0.56%
交易中 （美東）報價延遲15分鐘
23.66B總市值
0.17本益比TTM
關於 Takeda Pharmaceutical Co Ltd 公司
武田藥品株式會社是一家日本公司，主要從事藥品的研發、製造、銷售和許可。公司專注於胃腸道疾病、罕見疾病、血漿衍生物（免疫疾病）、腫瘤學（癌症）和神經科學（神經精神疾病）的主要業務領域。公司專注於三個研發領域：創新生物製藥，重點關注胃腸道和炎症疾病、神經科學和腫瘤學，以及血漿衍生物和疫苗。大多數藥品用於治療重點疾病領域和血漿衍生物領域的罕見疾病。公司在日本、美國、歐洲和中國開展業務。
公司簡介
公司代碼TAK
公司名稱Takeda Pharmaceutical Co Ltd
上市日期May 16, 1949
CEOMr. Christophe Weber
員工數量47455
證券類型Depository Receipt
年結日May 16
公司地址4F
城市CHUO-KU
上市交易所NYSE Consolidated
國家Japan
郵編103-8668
電話81332782111
網址https://www.takeda.com/
公司代碼TAK
上市日期May 16, 1949
CEOMr. Christophe Weber
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
收入明細
單位: JPY更新時間: 7月6日 週日
單位: JPY更新時間: 7月6日 週日
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
業務JPY
名稱
營收
佔比
Pharmaceutical Business
4.50T
98.13%
Intellectual Property And Service Revenue
85.58B
1.87%
地區JPY
名稱
營收
佔比
United States
2.38T
51.94%
Europe And Canada (Country)
1.06T
23.03%
Japan
418.46B
9.13%
Latin America
235.85B
5.15%
China (Country)
191.74B
4.19%
其他
300.60B
6.56%
業務
地區
業務JPY
名稱
營收
佔比
Pharmaceutical Business
4.50T
98.13%
Intellectual Property And Service Revenue
85.58B
1.87%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
99.02%
持股股東
持股股東
佔比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
99.02%
股東類型
持股股東
佔比
Investment Advisor
1.76%
Hedge Fund
0.35%
Investment Advisor/Hedge Fund
0.24%
Research Firm
0.15%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
其他
97.46%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
2023Q1
627
84.81M
2.73%
-21.74M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Capital Research Global Investors
13.20M
0.42%
+38.49K
+0.29%
Mar 31, 2025
Parametric Portfolio Associates LLC
5.29M
0.17%
+157.07K
+3.06%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.81M
0.12%
+478.81K
+14.38%
Mar 31, 2025
UBS Financial Services, Inc.
1.70M
0.05%
+105.99K
+6.63%
Mar 31, 2025
Brandes Investment Partners, L.P.
3.50M
0.11%
+464.56K
+15.28%
Mar 31, 2025
Renaissance Technologies LLC
3.16M
0.1%
+78.30K
+2.54%
Mar 31, 2025
Aperio Group, LLC
2.63M
0.08%
+426.92K
+19.37%
Mar 31, 2025
Goldman Sachs Asset Management, L.P.
2.89M
0.09%
+577.36K
+24.92%
Mar 31, 2025
First Trust Advisors L.P.
2.76M
0.09%
-484.98K
-14.96%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
VanEck Pharmaceutical ETF
4%
SGI Enhanced Global Income ETF
0.96%
Adasina Social Justice All Cap Global ETF
0.51%
Invesco Zacks Multi-Asset Income ETF
0.49%
ActivePassive International Equity ETF
0.47%
First Trust Value Line Dividend Index Fund
0.43%
Avantis International Equity ETF
0.06%
Avantis Responsible International Equity ETF
0.06%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
查看更多
VanEck Pharmaceutical ETF
佔比4%
SGI Enhanced Global Income ETF
佔比0.96%
Adasina Social Justice All Cap Global ETF
佔比0.51%
Invesco Zacks Multi-Asset Income ETF
佔比0.49%
ActivePassive International Equity ETF
佔比0.47%
First Trust Value Line Dividend Index Fund
佔比0.43%
Avantis International Equity ETF
佔比0.06%
Avantis Responsible International Equity ETF
佔比0.06%
Roundhill GLP-1 & Weight Loss ETF
佔比0%
DFA Dimensional International Core Equity 2 ETF
佔比0%
分紅派息
近5年累計派現
1.44T
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
